BBA
NTLA icon

Baker Bros. Advisors’s Intellia Therapeutics NTLA Stock Holding History

Baker Bros. Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,746,674
Closed -$47.4M – 94
2025
Q3 		$47.4M Buy
2,746,674
+71,000
+3% +$874K 0.34% 29
2025
Q2 		$25.1M Buy
2,675,674
+2,031,558
+315% +$16.7M 0.24% 33
2025
Q1 		$4.58M Hold
644,116
– – 0.05% 60
2024
Q4 		$7.51M Buy
+644,116
New +$10.1M 0.08% 61
2021
Q1 		– Sell
-111,296
Closed -$6.05M – 129
2020
Q4 		$6.05M Sell
111,296
-10,942
-9% -$397K 0.02% 88
2020
Q3 		$2.43M Sell
122,238
-6,300
-5% -$131K 0.01% 99
2020
Q2 		$2.7M Hold
128,538
– – 0.01% 93
2020
Q1 		$1.57M Hold
128,538
– – 0.01% 95
2019
Q4 		$1.89M Hold
128,538
– – 0.01% 85
2019
Q3 		$1.72M Hold
128,538
– – 0.01% 88
2019
Q2 		$2.1M Hold
128,538
– – 0.01% 85
2019
Q1 		$2.19M Hold
128,538
– – 0.01% 78
2018
Q4 		$1.75M Sell
128,538
-64,000
-33% -$1.19M 0.01% 76
2018
Q3 		$5.51M Sell
192,538
-354,384
-65% -$10.3M 0.04% 69
2018
Q2 		$15M Sell
546,922
-286,873
-34% -$6.95M 0.11% 50
2018
Q1 		$17.6M Sell
833,795
-311,658
-27% -$7.66M 0.15% 44
2017
Q4 		$22M Buy
1,145,453
+83,333
+8% +$1.92M 0.19% 43
2017
Q3 		$26.4M Hold
1,062,120
– – 0.21% 32
2017
Q2 		$17M Hold
1,062,120
– – 0.15% 36
2017
Q1 		$15M Hold
1,062,120
– – 0.12% 37
2016
Q4 		$13.9M Hold
1,062,120
– – 0.14% 40
2016
Q3 		$18.1M Hold
1,062,120
– – 0.16% 37
2016
Q2 		$22.7M Buy
+1,062,120
New +$28.3M 0.24% 31

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baker Bros. Advisors's NTLA Position: Q4 2025 in Review

Baker Bros. Advisors sold out of Intellia Therapeutics (NTLA) in Q4 2025, closing a stake of 2,746,674 shares — an estimated $47.4M sold.

Baker Bros. Advisors first reported a position in NTLA in Q2 2016 and held it in 23 quarters. The position peaked at $47.4M in Q3 2025. 292 funds tracked by Wall St. Rank hold NTLA as of Q4 2025.

  • Baker Bros. Advisors reported no remaining Intellia Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Baker Bros. Advisors sold 2,746,674 Intellia Therapeutics shares in Q4 2025, an estimated $47.4M.
  • Baker Bros. Advisors first reported a position in Intellia Therapeutics in Q2 2016 and held it in 23 quarters.
  • Baker Bros. Advisors's Intellia Therapeutics position peaked at $47.4M in Q3 2025.
  • 292 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2025.

Based on Baker Bros. Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.